Drug Approval | October 18, 2023
Glenmark's current portfolio consists of 188 products authorized for distribution in the US
Lupin enters into BTA with Lupin Manufacturing Solutions
The USFDA inspectors issued the observations after a product pre-approval inspection of the biologics facility in Bachupally
Lupin is exclusive first-to-file and may be eligible to receive a 180-day exclusivity period at product launch
Ayush Minister launched month long ayurveda celebration drive of Ministry of Ayush
The NDA filing for deuruxolitinib with the U.S. FDA is based on two pivotal Phase III trials
Dozee Pro Ex will offer Ambulatory patient monitoring for a seamless continuum of patient monitoring across different care settings
The company had submitted a comprehensive Corrective and Preventive Action (CAPA) plan in September 2022
Sugammadex Injection is indicated for the reversal of neuromuscular blockade induced by rocuronium bromide and vecuronium bromide
Subscribe To Our Newsletter & Stay Updated
